Advertisement

Pyoderma Gangrenosum

  • Clio DessiniotiEmail author
  • Andreas D. Katsambas

Abstract

Pyoderma gangrenosum (PG) is a rare, chronic, neutrophilic skin disease of unknown origin, characterized by painful, sterile, necrotic ulcers with violaceous undermined borders. It belongs to the group of neutrophilic dermatoses, and it has been characterized as a cutaneous autoinflammatory disease. PG is idiopathic in 40–50 % of patients; however, in the remaining cases, it may be associated with underlying diseases including ulcerative colitis, Crohn’s disease, leukaemia, monoclonal gammopathy, rheumatoid arthritis or immunodeficiencies. PG has been reported as part of PAPA, PASH and PAPASH syndromes. Four clinical variants of PG have been described: classic (ulcerative), pustular, bullous and vegetative. Extracutaneous pulmonary and splenic neutrophilic infiltrates may rarely occur in patients with PG. Despite the paucity of randomized, controlled trials and the lack of a standardized treatment algorithm for PG, systemic corticosteroids and cyclosporine are often used for severe disease.

Keywords

Pyoderma gangrenosum Neutrophilic Autoinflammatory Painful Ulcer Prednisolone Cyclosporine 

Further Reading

  1. Boussofara I, Gammoudi R, Ghariani N, et al. Familial pyoderma gangrenosum in association with common variable immunodeficiency. Br J Dermatol. 2013;169:944–6.CrossRefGoogle Scholar
  2. Braun-Falco M, Kovnerystyy O, Lohse P, et al. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) – a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409–15.CrossRefGoogle Scholar
  3. Brocq L. Nouvelle contribution a l’étude du phagédénisme géométrique. Ann Dermatol Syphiligr. 1916;6:1–39.Google Scholar
  4. Brooklyn TN, Dunnill MG, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomized, double blind, placebo controlled trial. Gut. 2006;55:505–9.CrossRefGoogle Scholar
  5. Chen W, Obermayer-Pietsch B, Hong J-B, et al. Acne-associated syndromes: models for better understanding of acne pathogenesis. J Eur Acad Dermatol Venereol. 2011;25:637–46.CrossRefGoogle Scholar
  6. Davatchi F, Assaad-Khalil S, Calamia KT, et al. The international criteria for Behcet’s disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28:338–47.CrossRefGoogle Scholar
  7. Field S, Powell F, Young V, et al. Pyoderma gangrenosum manifesting as a cavitating lung lesion. Clin Exp Dermatol. 2008;33:418–21.CrossRefGoogle Scholar
  8. Foley CC, Laing M. Paraneoplastic pyoderma gangrenosum successfully treated with minocycline and low-dose steroids. J Eur Acad Dermatol. 2014. doi: 10.1111/jdv.12384 [Epub ahead of print].CrossRefGoogle Scholar
  9. Goldminz AM. Severely recalcitrant pyoderma gangrenosum successfully treated with ustekinumab. J Am Acad Dermatol. 2012;67:e237–8.CrossRefGoogle Scholar
  10. Koshelev MV, Garrison PA, Wright TS. Concurrent hidradenitis suppurativa, inflammatory acne, dissecting cellulitis of the scalp, and pyoderma gangrenosum in a 16-year-old boy. Pediatr Dermatol. 2013;31:e20–1.CrossRefGoogle Scholar
  11. Li J, Kelly R. Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent. J Am Acad Dermatol. 2013;69:565–59.CrossRefGoogle Scholar
  12. Marzano AV, Ishak RS, Saibeni S, et al. Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet’s syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol. 2013a;45:202–10.Google Scholar
  13. Marzano AV, Trevisan V, Gattorno M, et al. Pyogenic arthritis, pyoderma gangrenosum, acne and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene. JAMA Dermatol. 2013b;149:762–4.Google Scholar
  14. Marzano AV, Borghi A, Stadnicki A, et al. Cutaneous manifestations in patients with inflammatory bowel disease: pathophysiology, clinical features, and therapy. Inflamm Bowel Dis. 2014;20:213–27.CrossRefGoogle Scholar
  15. Posso-De Los Rios C, Pope E. New insights into pustular dermatoses in pediatric patients. J Am Acad Dermatol. 2014;70:767–73.CrossRefGoogle Scholar
  16. Reichrath J, Bens G, Bonowitz A, Tilgen W. Treatment recommendations for pyoderma gangrenosum: an evidence-based review of the literature based on more than 350 patients. J Am Acad Dermatol. 2005;53:273–83.CrossRefGoogle Scholar
  17. Ruocco E, Sangiuliano S, Gravina AG, et al. Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol. 2009;23:1008–17.CrossRefGoogle Scholar
  18. Singh M, Andrew SM, Lear JT. Infliximab as a treatment for recalcitrant pyoderma gangrenosum. Clin Exp Dermatol. 2004;29:196–7.CrossRefGoogle Scholar
  19. Wise CA, Gillum JD, Seidman CE, et al. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorder. Hum Mol Genet. 2012;11:961–9.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of DermatologyAndreas Syggros Hospital, University of AthensAthensGreece
  2. 2.1st Department of Dermatology and VenereologyUniversity of Athens School of Medicine, “A. Sygros” Hospital for Skin and Venereal DiseasesAthensGreece

Personalised recommendations